SB1317 (TG-02) | B3218

SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 with IC50 of 13, 73, and 56 nM, respectively. SB1317 may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9).

SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 with IC50 of 13, 73, and 56 nM, respectively. SB1317 may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9).

B3218 | SB1317 (TG-02) DataSheet

Alternate Name/Synonyms: (16E)-14-methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene,Zotiraciclib

Appearance: Crystalline solid

Formulation:

CAS Number: 1204918-72-8

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₃H₂₄N₄O

Molecular Weight: 372.46

Cell-Permeable?: TRUE

Purity: ≥98%

Solubilities: >20 mg/ml DMSO

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: A potent inhibitor of CDK2, JAK2, and FLT3

MDL Number:

PubChem CID: 16739650

SMILES: CN1CC=CCCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1

InChi: InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+

InChi Key: VXBAJLGYBMTJCY-NSCUHMNNSA-N